Detalhe da pesquisa
1.
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Oncologist
; 24(4): 563-569, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30541754
2.
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis.
Oncologist
; 22(3): 311-317, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28232599
3.
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Oncologist
; 22(6): 743-749, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28424325
4.
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Oncologist
; 20(8): 960-6, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26070917
5.
Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma.
Oncologist
; 23(2): 139-142, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180460
6.
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.
J Clin Oncol
; 37(30): 2730-2737, 2019 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31116675
7.
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.
J Clin Oncol
; 23(22): 5099-107, 2005 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15983396
8.
Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
Urol Oncol
; 33(3): 137-42, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25613202
9.
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer.
Bladder Cancer
; 1(2): 133-136, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-27088122
10.
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Clin Cancer Res
; 20(1): 9-14, 2014 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24190979
11.
Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary.
Clin Cancer Res
; 19(22): 6067-73, 2013 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24141628
12.
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Clin Cancer Res
; 19(24): 6650-6, 2013 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24150234
13.
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Clin Cancer Res
; 18(14): 3722-30, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22665903